Clinical trial · Observational
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)
IMpact of BrcA Status on Survival in Adjuvant Breast Cancer (IMBASSA)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Relationship between the presence of the BRCA mutation (BReast Cancer) and outcomes is unclear in high-risk early breast cancers (BC). This study is a multi-center retrospective cohort of patients treated in region Franche-Comté for an early BC by neoadjuvant and/or adjuvant chemotherapy. The primary aim was to describe clinical and pathological characteristics considering BRCA mutated (BRCAm) patients versus BRCA wild type (BRCAwt) patients or untested patients. The second objective was to assess the prognostic impact of germinal BRCAm in this high-risk population.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BRCA1 Mutation | — | UNRESOLVED | — |
| BRCA2 Mutation | — | UNRESOLVED | — |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BRCA mutation | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients treated by chemotherapy for an early breast cancer
- description
- Patients (Women or Men) older than 18 years old, histologically confirmed invasive early breast cancer, treated by neo-adjuvant and/or adjuvant chemotherapy with the first cure of chemotherapy received between January 1st, 2003 and December 31th, 2013 were included.
- interventionNames
- Genetic: BRCA mutation
Primary outcomes (14)
- measure
- Age of diagnosis
- timeFrame
- one day
- description
- The date from the date of birth to the date of pathological diagnosis (Years)
- measure
- Pathological tumor size
- timeFrame
- one day
- description
- Pathological tumoral size after partial or complete surgery Pathological size in millimeters after complete surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients older than 18 years old, * Histologically confirmed invasive early breast cancer * Neo-adjuvant and/or adjuvant chemotherapy with the first cure of chemotherapy received between January 1st, 2003 and December 31th, 2013 Exclusion Criteria: * Clinical, radiological or histological confirmed metastatic disease * Non-invasive breast cancer, * Patients who received incomplete treatment * Patients who did not speak French
References
Publications (0)
Data not yet available